Held by 5 specialist biotech funds
High Convergence**Signal Note: Driehaus Growth Entry into PTGX** Driehaus Capital's $96M new position in Protagonist Therapeutics signals conviction in PN-943, an oral, selective MET receptor antagonist in Phase 2 for celiac disease, addressing a significant unmet need with limited approved therapies beyond dietary restriction.
AI analyst context — unlock full analysis
Unlock dollar amounts, share counts, and AI context with a free trial.
# Signal Note: OrbiMed Initiation of PTGX OrbiMed's $1.9M entry into Protagonist suggests conviction in its pipeline, particularly PN-943 (oral antagonist for moderate-to-severe ulcerative colitis in Phase 2b, readout expected 2H 2024) and PN-212 (PN2-β integrin inhibitor for celiac disease, Phase 2 ongoing). The initiation by a top-tier healthcare allocator signals confidence in oral small-molecule intestinal disease candidates where competition remains limited versus biologics. Near-term catalyst dependency on UC efficacy/safety data will likely drive near-term volatility.
+ 3 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial**Insider Sale — PTGX — CMO Molina, $1.57M** CMO sold 15,000 shares at $104.79, a meaningful dollar amount though insider sales at elevated prices are often liquidity/diversification-driven rather than bearish signals, particularly for a C-suite officer with concentrated equity exposure. Worth noting PTGX has had a strong run on rusfertide progress toward potential approval in polycythemia vera, so this could simply be harvesting gains near highs. Monitor for additional insider sales or any clustering among other executives, which would shift this from routine to potentially informative.
**Insider Transaction Note — PTGX** CFO Ali Asif sold ~$2.6M in shares at $104.24, a meaningful disposal that warrants monitoring but requires context: CFO-level sales often reflect diversification, tax planning, or liquidity needs rather than bearish conviction, particularly after PTGX's significant price appreciation. Worth checking whether this aligns with a 10b5-1 pre-scheduled plan, which would substantially reduce the informational signal. On its own, a single CFO sale is low-to-moderate signal — it becomes more meaningful if clustered with additional insider dispositions in the near term.
**Insider Sale – Protagonist Therapeutics (PTGX) – Harold Selick, $2.52M** Selick, a non-executive insider, sold 24,000 shares at $105, a meaningful liquidation at elevated price levels for a mid-cap biotech. While insider sales are lower-signal than purchases — often driven by diversification, tax planning, or liquidity needs — the size warrants monitoring, particularly if other insiders follow. Check whether this was executed under a pre-planned 10b5-1 trading plan, which would substantially reduce the informational content of the transaction.